Protein kinase casein kinase II (CK2) is increased in response to diverse growth stimuli, as well as being elevated in many human cancers examined. We have demonstrated that CK2 is a key survival factor that protects human colon carcinoma cells from TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. We determined that inhibition of CK2 phosphorylation events by DRB (5,6-dichlorobenzimidazole) resulted in dramatic sensitization of tumor cells to TRAIL-induced apoptosis, in the absence of effects in normal cells. Sensitization was caspase dependent, and independent of regulation via NF-jB. Further, inhibition of phosphorylation by CK2 did not modify the expression level of antiapoptotic proteins. Analysis of TRAIL-induced deathinducing signaling complex (DISC) formation demonstrated enhanced formation of the DISC, enhanced cleavage of caspase-8 and cleavage of Bid in the presence of DRB, thereby facilitating the release of proapoptotic factors from the mitochondria with subsequent downregulation of the expression of XIAP and c-IAP1. Further, silencing of CK2a in HT29 cells following transfection of CK2a shRNA abrogated CK2 kinase activity while simultaneously increasing TRAIL sensitivity. These findings demonstrate that CK2 plays a critical antiapoptotic role by conferring resistance to TRAIL at the level of the DISC.
Introduction
TNF-related apoptosis-inducing ligand (TRAIL) binds to the apoptosis-inducing receptors DR4 or DR5, which are type I transmembrane receptors, expressed at the cell surface. The mechanism of induction of apoptosis by TRAIL is believed to be similar to that of TNF-a and FasL, thereby requiring ligand-induced aggregation of DR4 and DR5 via their death domains on the cytoplasmic side of the receptors . The death domains in turn orchestrate the assembly of adaptor components including the Fas-associated protein with death domains (FADD), which activates caspases by interaction of caspase recruitment domains from the adaptor proteins with prodomains of the caspases . The adaptor proteins involved in TRAIL-induced apoptosis have been controversial, with some reports suggesting that FADD and the TNFR-associated death domain were not involved (Marsters et al., 1996) , whereas others have demonstrated direct binding of FADD and TNFR-associated death domain protein to the TRAIL receptor (Schneider et al., 1997; Wajant et al., 1998) . The sensitivity of type II cells to death receptor-mediated apoptosis may be modulated by different mechanisms (Scaffidi et al., 1998) , in particular by phosphorylation-based signaling pathways . Stimulation of the mitogenactivated protein kinase (MAPK) pathway has antagonized TRAIL-induced apoptosis downstream of Bid cleavage in human breast cancer MCF-7 cells (Sarker et al., 2001) . Conversely, inhibition of death receptormediated ERK1/2 activation was sufficient to sensitize human breast MCF-7 cells to apoptotic signaling induced by TRAIL (Sarker et al., 2002) . Phosphorylation has also been reported to interfere with the apoptotic cascade downstream of DISC activation but upstream of full cleavage of caspase-8 or the cleavage of Bid Varadhachary et al., 2001) .
Protein kinase CK2 (formerly casein kinase II) is a ubiquitously distributed and highly conserved protein serine/threonine kinase in eukaryotes (Padmanabha et al., 1990; Kikkawa et al., 1992) . It comprises two catalytic a or a 0 subunits and two regulatory b subunits that can form a holoenzyme (Allende and Allende, 1995) . In many human cancers that have been examined, as well as experimental tumors, CK2 activity has been found to be consistently enhanced (Munstermann et al., 1990; Faust et al., 1999; Landesman-Bollag et al., 2001) . This upregulation of CK2 in tumors is consistent with a role for CK2 in growth promotion, cellular transformation or in inhibiting apoptosis, although the latter still remains to be fully established. With regard to the role of CK2 in the functional inhibition of apoptosis, male mice in which the gene encoding the CK2a 0 subunit was disrupted demonstrated an increased number of apoptotic cells in testes (Xu et al., 1999) . Other studies have demonstrated a large increase in CK2 activity in the nuclear matrix of etoposide-treated cells that may reflect a protective response (Guo et al., 2001) . Downregulation of CK2 expression using antisense oligonucleotides resulted in a preferential decrease in CK2 localization within the nuclear compartment and the induction of apoptosis . Further, CK2-mediated phosphorylation of IkBa appears important in the promotion of NF-kB activation and survival of breast cancer cells (Romieu-Mourez et al., 2002) . CK2 may also play a constitutive protective role in Fas-mediated apoptosis. Recent studies have shown that CK2 can phosphorylate Bid close to the recognition site for caspase-8 cleavage, thereby preventing cells from undergoing apoptosis (Desagher et al., 2001) . Inhibition of CK2 accelerated Fas-induced apoptosis, while CK2 overexpression delayed the death of HeLa cells exposed to agonistic anti-Fas antibody. In this study, a mutant of Bid that cannot be phosphorylated was found to be highly sensitive to caspase-8-induced cleavage (Desagher et al., 2001) . Recent studies have found that CK2 promotes NF-kB-mediated expression of Bcl-xL and cancer cells with constitutive activation of CK2 exhibit a high Bcl-xL/tBid ratio and fail to undergo apoptosis in response to TRAIL (Ravi and Bedi, 2002) . Conversely, reduction of the Bcl-xL/tBid ratio by inhibition of CK2 using 5,6-dichlorobenzimidazole (DRB), the natural plant flavonoid, apigenin, or the anthraquinone derivative, emodin, has rendered such cancer cells sensitive to TRAIL-induced apoptosis (Ravi and Bedi, 2002) .
To further investigate mechanisms of resistance to TRAIL relevant to human colorectal carcinomas, we analysed the role of CK2 in the inherent resistance of human colorectal carcinoma cell lines to TRAIL. We have demonstrated that inhibition of CK2 function effectively sensitizes the cell lines to TRAIL-induced apoptosis at the level of the DISC by facilitating procaspase-8 cleavage.
Results

CK2 kinase activity in HT29 cells
CK2 was constitutively active in HT29 cells, as demonstrated by the level of activity of the endogenous kinase. Exposure of HT29 to the classic CK2 inhibitor, DRB (40 or 60 mM), resulted in inhibition of phosphorylation of the CK2-specific peptide substrate (RRREEETEEE; Figure 1 ). Inhibition of CK2 activity was also achieved by treatment with the plant flavonoid apigenin (40 or 60 mM), but not by the PKC inhibitor bisindoylmaleimide III (5 or 20 mM; Figure 1 ).
CK2 attenuates TRAIL-induced cell death
DRB, an inhibitor of CK2, was subsequently evaluated for the ability to sensitize human colon carcinoma cell lines to TRAIL-induced apoptosis during 24 h coincubation. Treatment with DRB (40 mM) 2 h prior to and during incubation with TRAIL (10-50 ng/ml) resulted in dramatic sensitization of HCT8, HCT116 and HT29 to TRAIL-induced cell death, increasing maximally to >80% (Figure 2 ). The effect was completely inhibited by the broad-spectrum caspase inhibitor z-VAD-fmk, (Figure 3a) , confirming the critical role of caspases in this process. Treatment with DRB alone, at the concentration required for sensitization (40 mM), was devoid of any significant cytotoxic activity. In contrast, the combination of TRAIL (50-300 ng/ml) and DRB (40 mM) was not cytotoxic to normal cells (human foreskin fibroblasts (HFF) and human umbilical vascular endothelial cells (HUVEC)) even at the highest TRAIL concentration (Figure 3b ). Data suggest that DRB interferes with CK2-regulated signaling pathways, increasing sensitivity of cancer cell lines, but not normal cells, to TRAIL-induced apoptosis.
CK2 activity does not modulate TRAIL-induced NF-kB activation
NF-kB has demonstrated potent antiapoptotic properties in TRAIL-induced apoptosis (Keane et al., 2000; Bernard et al., 2001; Trauzold et al., 2001) . In addition to promoting phosphorylation-induced degradation of IkBa, CK2 activates NF-kB transcriptional activity by phosphorylating RelA/p65 (Wang et al., 2000) . To evaluate whether the increased sensitivity to TRAILinduced apoptosis in the presence of CK2 inhibitors may be mediated by inhibition of NF-kB function, CK2 regulates TRAIL sensitivity K Izeradjene et al TRAIL-induced NF-kB activation was examined in HT29 cells either in the absence or presence of the CK2 inhibitors DRB or apigenin. Employing electrophoretic mobility shift assays (EMSAs), an increase in NF-kB DNA-binding activity was detected upon stimulation with TRAIL (50 ng/ml; Figure 4a ). This induction was observed by 1 h after stimulation. The supershift EMSA demonstrated that TRAIL-induced NF-kB DNA-binding activity consisted mainly of p65/p50 heterodimers. The presence of CK2 inhibitors did not negatively affect TRAIL-induced NF-kB activation. NF-kB has also been reported to induce expression of the inhibitory proteins c-FLIP, Bcl-xL and XIAP (Almasan and Ashkenazi, 2003) . However, treatment of HT29 cells with DRB (40 mM) for up to 24 h did not modify the levels of expression of c-FLIP, Bcl-xL or XIAP (Figure 4b ). The levels of expression of additional proteins involved in TRAIL signaling pathways were also unchanged during the treatment (Figure 4b ). These data suggest that CK2-regulated, TRAIL-induced apoptosis is NF-kB independent.
TRAIL signaling is regulated by CK2 at the level of the receptor
To determine whether the constitutive expression of CK2 in HT29 cells demonstrated a role in regulating the expression of DR5 or the formation of the TRAILinduced DISC, we determined cell surface expression of TRAIL receptors by flow cytometry, or immunoprecipitation experiments for DISC formation, in which HT29 cells were exposed either in the absence or presence of DRB (40 mM) for 2 h. Cells were subsequently incubated with TRAIL (2 ml) for up to 2 h at 371C. In HT29 cells that were not exposed to DRB, DISC formation was detected at 60 min ( Figure 5a ). Pretreatment with DRB increased recruitment of DR5 to the DISC. This effect may cause more caspase-8 processing seen 60 min after TRAIL treatment in the presence of DRB (Figure 5a ). This was not associated with DRB-induced elevation of DR5 expression at the cell surface as determined by flow cytometry (Figure 5b ) or in the cytosol (Figure 4b ). DR4 was not expressed at significant levels at the cell surface ( Figure 5b ). In addition, in HT29 cells treated with DRB þ TRAIL, the DISC remained stable at 120 min, while in cells treated with TRAIL alone, caspase-8 was no longer recruited to the DISC. In HCT8 cells, pretreatment with DRB increased the recruitment of DR5 and facilitated procaspase-8 processing 120 min after TRAIL treatment ( Figure 5a ). Similar to HT29 cells, the DISC remained stable at 120 min, while in cells treated with TRAIL alone, caspase-8 was no longer recruited to the DISC. In both cell lines, FADD was below the level of detection within the DISC (Figure 5a ; Lacour et al., 2003) .
Influence of DN-FADD, Bcl-xL or Bcl-2 overexpression
Using isogenic HT29 cell lines, TRAIL (50 ng/ml) combined with DRB (40 mM) significantly enhanced the cleavage of caspase-8, Bid, caspase-9, caspase-3 and 
Inhibition of CK2 facilitates TRAIL-induced release of proapoptotic factors from the mitochondria
The kinetics of release of mitochondrial proteins into the cytosol was subsequently examined during DRB-induced sensitization of HT29 cells to TRAILinduced apoptosis (Figure 7 ). In cells treated with TRAIL alone (50 ng/ml), slight release of cytochrome c, Smac/DIABLO and HtrA2/Omi could be detected in the cytosol. In contrast, in cells treated with TRAIL in the presence of DRB (40 mM), the release of proapoptotic factors into the cytosol was increased by 4 h following treatment. Exposure to DRB alone had no effect on the release of proapoptotic factors ( Figure 7 ). The release of AIF was also enhanced in TRAIL-treated cells in the presence of DRB. Inhibition or degradation of XIAP and c-IAP1 was observed only in cells treated with the combination TRAIL and DRB, and was evident by 3 h after the initiation of treatment. To determine whether shRNA could modulate the expression of CK2a, CK2 kinase activity and TRAILinduced cell death, several retroviral vectors were generated that contained shRNA targeting CK2a (designated sh1148, sh447, sh909). Transfection of shRNAs into HT29 cells resulted in varying levels of suppression of CK2a expression, with sh909 and sh447 achieving the greatest reduction in CK2a levels ( Figure 8a ). No effect was observed on the expression of b-actin. When CK2 kinase activity was determined in cell lysates from shRNA-transfected cells, low kinase activity was detected in sh447-and sh909-transfected cells (67% decrease), and intermediate activity (33% decrease) in sh1148-transfected cells, in comparison to vector control cells (Figure 8b ). It was next determined whether reduction in CK2a expression levels with shRNA could sensitize HT29 cells to TRAIL-induced cell death. Transfected cells were treated for 24 h with increasing concentrations of TRAIL (10-100 ng/ml). Transfection of HT29 with sh447 or sh909 resulted in dramatic sensitization of HT29 cells to TRAIL-induced apoptosis approaching 80%, while transfection with sh1148 did not decrease kinase activity sufficiently to have any effect on TRAIL sensitivity, thereby acting as a negative control (Figure 8c ).
Discussion
In many human cancers examined, as well as in experimental tumors, CK2 activity has been found to be consistently elevated (Munstermann et al., 1990; Faust et al., 1999; Landesman-Bollag et al., 2001) . Upregulation of CK2 in tumors is consistent with a role for CK2 in cell growth promotion or in the inhibition of apoptosis. The results of the present study have brought forth more direct evidence for an antiapoptotic function for CK2. We have demonstrated that inhibition of CK2 activity leads to sensitization of tumor cells derived from human colon carcinomas to TRAIL-induced apoptosis by controlling the most apical point in the TRAIL signaling pathway, involving the recruitment of procaspase-8 to the DISC at the level of the TRAIL receptors. We demonstrated that inhibition of CK2 resulted in enhanced caspase-8 cleavage and significantly increased TRAIL-induced apoptosis. Recent studies have shown that CK2 can phosphorylate Bid in the vicinity of the recognition site for caspase-8, and that this phosphorylation renders Bid resistant to cleavage by caspase-8 and protects cells from Fas-induced apoptosis (Desagher et al., 2001) . This has been shown to contribute to CK2-induced inhibition of TRAIL-induced apoptosis in malignant cells (Ravi and Bedi, 2002) , and in the current investigation, may also contribute to the acceleration of both caspase-8-mediated Bid cleavage and TRAIL-induced apoptosis in cells treated with the CK2 inhibitor, DRB. Ruzzene et al. (2002) and others (Desagher et al., 2001; KrippnerHeidenreich et al., 2001) have suggested that CK2 could counteract apoptosis by a general mechanism consisting of the generation of phosphorylated sites resistant to caspase cleavage. However, we have demonstrated that additional sites also exist, upstream of caspase activation. CK2 can also promote cell survival by regulating NFkB via two pathways: the first involves removal of the NF-kB inhibitor IkB from the NF-kB-IkB complex by phosphorylating IkB proteins, thereby promoting their degradation (McElhinny et al., 1996) . The second is by direct phosphorylation of NF-kB proteins including p65, resulting in their increased transcriptional potential (Wang et al., 2000) . Recently, it was shown in Hs578 breast cancer cells that CK2 promotes NF-kB-mediated expression of Bcl-xL, which in turn sequesters tBid and curtails its ability to activate Bax. Conversely, reduction of the Bcl-xL/tBid ratio by CK2 inhibitors sensitized these cells to TRAIL-induced apoptosis (Ravi and Bedi, 2002) . Our results indicate that in colon carcinoma HT29 cells, CK2 does not promote NF-kB-mediated expression of Bcl-xL or other survival factors involved in TRAIL signaling pathways. Further, CK2 inhibition demonstrated no direct effect on TRAIL-induced NFkB activation. These data clearly indicate that alternative signaling pathways modulated by CK2 are involved in influencing cellular sensitivity to TRAIL. In the current study, overexpression of DN-FADD in HT29 cells abrogated TRAIL-induced cell death in the presence of DRB, confirming that events upstream of the mitochondria were involved in the mechanism of DRB-induced sensitization to TRAIL-induced apoptosis. In HT29 cells overexpressing Bcl-2, TRAIL-induced apoptosis in the presence of DRB was completely inhibited. Caspase-8 was processed to its p43 and p41 forms, although to a lesser extent than in control cells. Interestingly, cleavage of caspase-3 and PARP was not observed in cells overexpressing Bcl-2, suggesting abrogation of caspase-3 activity. Similar to previous reports (Scaffidi et al., 1998 (Scaffidi et al., , 1999 Sun et al., 2002) , Bcl-2 inhibited Fas-mediated apoptosis in Jurkat T cells, and this appeared to correlate with a block in caspase-3 activity. It is possible that active caspase-3 initiates an amplification loop, which could result in additional processing of caspase-8. We have also demonstrated that inhibition of CK2 enhances TRAIL-induced release of cytochrome c, Smac/DIABLO and HtrA2/Omi with concomitant inhibition of the function of members of the IAP family. Therefore, activation of the mitochondrial apoptotic pathway is required for the execution of TRAIL-induced apoptosis in colon carcinoma cells. We have demonstrated that introduction of an shRNA duplex targeting CK2a decreases the expression of the CK2a subunit, thereby restoring TRAIL sensitivity in HT29 colon cancer cell lines, unequivocally demonstrating the importance of CK2 function in attenuating TRAIL-induced apoptosis.
In summary, we propose an additional mechanism promoted by CK2 upstream of the function of both caspase-8 and Bid, in mediating TRAIL resistance at the level of the receptor. Decreased Bid processing found in TRAIL-stimulated, TRAIL-resistant cells may arise, at least in part, from the limited levels of procaspase-8 recruited to, and the active caspase-8 generated at, the level of the DISC. Inhibition of CK2 function resulted in enhanced processing of procaspse-8 at the DISC. In HT29 human colon carcinoma cells, this mechanism is clearly independent of survival signaling pathways that involve NF-kB activation or NF-kBinduced expression of survival proteins including c-FLIP, Bcl-2 or Bcl-xL. Inhibition of NF-kB can sensitize cells for TNFa-or TRAIL-induced apoptosis, depending on the cell type, suggesting that distinct signaling pathways modulate the effect of TRAIL in a cell type-specific manner (Beg et al., 1995; Jeremias and Debatin, 1998) . Modulation of CK2, a critical survival factor in many human cancers that have been examined, appears to be important in circumventing resistance of human cancer cells to TRAIL-induced apoptosis, and may be more generally applicable to many other types of human cancers.
Materials and methods
Cell lines
HT29, HCT116 and HCT8 human colon carcinoma cell lines were obtained from ATCC. HUVEC and HFF were obtained from Dr Jeffrey Dome, St Jude Children's Research Hospital. Cell lines were maintained in RPMI 1640 medium (Gibco) supplemented with 10% fetal calf serum and 2 mM glutamine.
Kinase assays
The kinase assay is based on phosphorylation of a CK2-specific peptide substrate using the transfer of the g-phosphate of [g-32 P]GTP by CK2 kinase. Whole-cell extracts from HT29 cells (20 mg) in 1 ml were assayed for CK2 kinase activity at 301C for 15 min in kinase buffer (100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 50 mM KCl, 20 mM MgCl 2 , 100 mM Na 3 VO 4 ), 1 ml [g-32 P]GTP solution (to give 5 mCi/ml and 5 mM GTP total) and 1 mM peptide as substrate. The phosphorylated substrate was separated from residual [g-32 P]GTP using P81 phosphocellulose paper. Incorporation of [ 32 P] into the substrate was measured using a scintillation counter. CK2-specific peptide substrate RRREEETEEE was synthesized by the Hartwell Center, St Jude Children's Research Hospital. Inhibition of CK2 activity was achieved by incubation of cells with DRB (40 mM; Calbiochem; Ravi and Bedi, 2002) or apigenin (60 mM; Sigma-Aldrich, St Louis, MO, USA; Ravi and Bedi, 2002) .
Production of recombinant human TRAIL
The cDNA of the extracellular domain of TRAIL corresponding to amino acids 114-281 was subcloned into the pET17/b (Novagen) bacterial expression vector and expressed in the BL21(DE3)pLysE (Novagen) bacterial host. Following induction of TRAIL expression using isopropyl-b-thio-galactosidase (1 mM), bacterial pellets were harvested, and TRAIL was purified following passage through a nickel column (Ni-NTA) followed by a size exclusion column (Amersham), according to published procedures (Scaffidi et al., 1998; Ashkenazi et al., 1999) .
Analysis of cell death
Cells were plated at a density of 200 000 cells/well in 12-well plates, and after overnight attachment were treated with TRAIL (10-100 ng/ml) either in the absence or the presence of the CK2 inhibitors for up to 24 h. Apoptotic cells were determined by Annexin V-propidium iodide staining. Cells were stained with 10 ml of Annexin V-APC (Becton Dickinson & Co, San Jose, CA, USA) and 10 ml of propidium iodide (50 ng/ml) according to the manufacturer's instructions, incubated for 15 min at room temperature in the dark, and immediately analysed. HT29 cells were also pretreated with the pancaspase inhibitor z-VAD-fmk (50 mM; Enzyme Systems Products, Livermore, CA, USA) for 1 h prior to TRAIL treatment. In some experiments, apoptotic cells were also determined by forward side-scatter following propidium iodide staining (Ehrhardt et al., 2003) .
Analysis of DISC
Immunoprecipitation of receptor complexes following treatment of cells for time periods of up to 2 h with 0.35 mg/ml flagtagged TRAIL (Upstate), and analysis of components of the DISC, were conducted as described by us previously (Petak et al., 2003) .
Western blot analysis
Western blot analyses were conducted as described (Scaffidi et al., 1998) . The primary antibody to detect CK2a/a 0 was from CK2 regulates TRAIL sensitivity K Izeradjene et al DB Transduction Laboratories. Primary antibodies for the detection caspase-8, caspase-9, Smac/DIABLO and XIAP were from MBL. Anti-c-IAP1 was purchased from Alexis Biochemicals. Primary antibodies for caspase-3, Bid and PARP were purchased from BD Pharmingen, and for cytochrome c, the monoclonal antibody was purchased from Clontech. Anti-AIF was from Santa Cruz, and Anti-HtrA2/ Omi antibody was kindly provided by Dr Emad Alnemri (Kimmel Cancer Institute, PA, USA). The secondary antibody employed was HRPO-conjugated sheep anti-mouse IgG1 (Amersham).
Determination of the effect of DRB on expression of DR4 and DR5 receptors
Cells were incubated at 371C for 2 h with DRB (40mM). After being washed once with ice-cold PBS, cells were detached by brief trypsinization, and incubated with monoclonal antibodies against DR4 (HS101), DR5 (HS201) or control murine IgG1, followed by phycoerythrin-conjugated goat anti-mouse immunoglobulin (Alexis Biochemicals). Cells (10 4 ) were subsequently analysed by FACScan.
Plasmid vectors and transfection
The retroviral expression vectors pMSCV-I-GFP (expressing GFP) and pMSCV-DN-FADD (expressing the death domain only of FADD) were kind gifts from Dr Jill M Lahti and Dr Vincent J Kidd (St Jude Children's Research Hospital, Memphis, TN, USA). The retroviral expression vector pMSCV-Bcl-xL and pMSCV-Bcl-2 were kindly provided by Dr John Cleveland (St Jude Children's Research Hospital, Memphis, TN, USA). Kinase-inactive CK2a 0 (K69), a gift from Dr David W Litchfield (University of Western Ontario, London, Ontario, Canada), was subcloned into the pMSCV-I-GFP vector. Retroviral supernatants were prepared as described previously (Persons et al., 1999) . HT29 cells were incubated overnight in a 50% mixture of RPMI 1640 and retroviral supernatants in the presence of polybrene (8 mg/ml), subsequently washed, placed in fresh medium, and after 48 h, cells were sorted for GFP expression by fluorescence-activated cell sorting (FACS). The expression of Bcl-2, Bcl-xL, and DN-FADD were confirmed by Western blotting.
Electrophoretic mobility shift assay
Nuclear extracts were obtained using a modified Dignam protocol (Lee et al., 1988) . A double-stranded oligonucleotide containing the DNA-binding site for the NF-kB protein (5 0 -GGGAGTTGAGGGGACTTTCCCAGGC-3 0 ) was 3 0 -endlabeled using [g 32 P]dCTP and purified using a Sephadex G-25 column (Roche). Nuclear extracts (15 mg) were mixed with 10 5 c.p.m. of labeled probe and poly-dIdC (2 mg; Sigma; to prevent nonspecific binding) in 20 ml of buffer (20 mM HEPES, pH 7.8, 420 mM KCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, pH 8.0, 25% glycerol, 1 mM PMSF, 1 mM DTT). The binding reaction was carried out at 41C for 20 min, RT for 10 min and samples were subsequently analysed on a 4% nondenaturing acrylamide gel. For antibody supershift analysis, the binding reaction was first performed in the absence of the probe, the appropriate antibody was added and the mixture was incubated for 20 min at 41C. The probe was then added. The reaction was incubated an additional 20 min at RT, and the complexes resolved by gel electrophoresis, as above. Antibodies used were anti-p50 subunit, sc-1190x; anti-p65 subunit, sc-109x (both antibodies were from Santa Cruz Biotechnology, Santa Cruz, CA, USA). The gels were dried and bands detected by autoradiography.
Plasmids expressing shRNAs and transfection
The shRNA sequences were designed using designated software found on the OligoRetriever Database and encoded inverted repeats of 27-29 bp separated by an 8-nucleotide spacer, which corresponded to nucleotides 1148-1176 (sh1148), 447-475 (sh447) and 909-937 (sh909) of the CK2a cDNA. The sequences were prepared by the Hartwell Center (St Jude Children's Research Hospital, Memphis, TN, USA). Sequences were subsequently ligated to the U6 promoter vector (pSHAg-1), compatible with the GATEWAY system (Invitrogen), which was used to transport the shRNA expression cassette into the recipient MSCV-I-GFP retroviral vector. HT29 cells were incubated overnight in a 50% mixture of RPMI 1640 and retroviral supernatants in the presence of polybrene (8 mg/ml). After a further 48 h, cells were evaluated for GFP expression using FACS. The U6 promoter vector pSHAG-1 and the recipient vector MSCV-I-GFP were kindly provided by Dr Gregory J Hannon (Cold Spring Harbor Laboratory, NY, USA). Design of shRNA primers from gene Accession numbers was conducted from the RNAi OligoRetriever Database at http://www.cshl.org/public/science/hannon.html.
Cellular fractionation
Cytosolic extracts were prepared using the ApoAlert kit (Clontech) with a Dounce homogenizer and subjected to centrifugation at 700 g to pellet nuclei. The postnuclear supernatant was centrifuged at 10 000 g to pellet the mitochondria-enriched heavy membrane fraction, and the resulting supernatant was further centrifuged at 100 000 g to obtain the cytosolic fraction. Total proteins (15 mg) were subjected to immunoblot analysis. Abbreviations CK2, casein kinase II; TRAIL, TNF-related apoptosisinducing ligand; GFP, green fluorescence protein; DISC, death-inducing signaling complex; DRB, 5,6-dichlorobenzimidazole; IAP, inhibitor of apoptosis protein; shRNA, short hairpin RNA.
